 |
|
|
 |
 |
 |
 |
Kinexum Metabolics, Inc. was formed in 2004 and is developing
compounds for the treatment of diabetes. INGAP peptide, an islet
neogenesis compound is in phase 2 development for the treatment of
type 1 and type 2 diabetes. (more>>)
|
 |
|
|
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
Kinexum Health Products, Inc. was formed in 2005 for the development and distribution of nutraceuticals and other natural health products (more>>)
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Home : Leadership
Leadership
Kinexum's leadership is based on embracing the value of diversity and the importance of relationships in facilitating meaningful transformation of individuals and organizations.
Founders
G. Alexander Fleming, MD
President and Chief Executive Officer
Lisa Jansa, MBA
Executive Vice President and Chief Operating Officer
Partners, Associates, and Advisors
John K. Whisnant, MD
Guenther Karmann, MD
Peter Damsbo, MD
Knut Zellerhoff, PhD
Barbara Gloersen
Lucy Jean, PhD
Radha Krishnan, PhD
Leo Pavliv
Jonathan Ma, PhD
Scott Rossi
Lynn Schaich
Mel Dong, PhD
John M. ("Jack") Davitt, MS
Scot Faulkner, MPA
Government Policy Affairs & Operations Management
Kevin Roche, JD, MBA
Strategy and Business Development
Copyright © 2004 Kinexum LLC | terms of use | privacy
|
|
|
|
|
|
|
|
|
Experienced team provides your organization with high level talent to fit your needs.
|
|
|
|
|
|
|
|
|
|
